The Role of Altered Long Noncoding Rnas in Overall Survival of Ovarian Cancer: A Systematic Review and Meta-Analysis Publisher Pubmed



Seyed Hosseini E^{1, 2} ; Alizadeh Zarei M^{1, 2} ; Haddad Kashani H^{1, 2} ; Milajerdi A³ ; Zare Dehghanani Z² ; Hassani Bafrani H¹ ; Nikzad H^{1, 2} Show Affiliations
Source: Pathology Research and Practice Published:2021

Abstract

In recent years, tremendous research efforts have been focused on investigating the effect of dysregulation of lncRNAs on cancer progression, most of which confirm a positive link. This inspired us to conduct the present meta-analysis to explore whether aberrant expression of multiple lncRNAs has a role in patients' outcome in ovarian cancer. This comprehensive meta-analysis pertains to the evaluation of association between dysregulated lncRNAs expression level with eventual outcome and clinicopathological characteristics of ovarian cancer patients. We systematically searched PubMed, Web of Science, and Scopus to find all eligible articles. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) for overall survival, disease-free survival and progression-free survival were measured with a fixed or random effects model. A total of 34 studies were included in the meta-analysis. Dysregulation of lncRNAs were contributed to shorter overall survival (34 studies, 1180 patients HR = 2.12, 95% CI: 1.73 ± 2.60, random-effects) in ovarian cancer. Furthermore, altered lncRNAs were also related to decreased progression-free survival (8 studies, 1180 patients HR: 1.88, 95% CI: (1.35–2.62) and disease-free survival (2 studies, 285 patients, HR: 6.07, 95% CI: 1.28–28.78) in this disease. Our analyses supported the robust prognostic significance of altered lncRNAs in ovarian cancer. However, more extended studies are encouraged to evaluate the clinical application potential of these lncRNAs in the prognosis evaluation of ovarian cancer. © 2021